3.2 Percentage of patients whose known adverse drug reactions are documented on the current medication chart

Purpose
This indicator addresses the effectiveness of processes to prevent further harm from known adverse drug reactions.

Background and evidence
An adverse drug reaction (ADR) is defined as: “a response to a medicinal product which is noxious and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease or for the restoration, correction or modification of physiological function”.\(^1\) This includes, but is not limited to, allergy and anaphylaxis to medicines.

The purpose of ADR documentation is to avoid further harm to patients who have previously experienced an ADR to that (or a similar) medicine. A literature review of medication safety in Australia identified a significant gap in the communication of ADRs to patients and other healthcare professionals in the acute health care sector.\(^2\)

The Australian National Inpatient Medication Chart (NIMC) was introduced in 2006 as a strategy to improve the safe use of medicines. An audit of the NIMC in 2012 demonstrated that completion of ADR documentation occurred in 79% of the NIMCs.\(^3\) This same study showed that, of those patients with previous documentation of an ADR, 11% were prescribed a medicine of a similar class. Another study showed that prescribing errors involving selection of a medicine to which a patient had had a previous ADR, decreased following implementation of the NIMC from 11.3% of patients to 4.6% (p=0.021).\(^4\)

Key definitions

**Known adverse drug reactions** refers to any ADR identified before or during the current admission that has been recorded in the medical record. Any ADR that may influence future therapeutic decision making, whether it involves a prescription medicine (including vaccines), over-the-counter medicine or complementary medicine, should be documented.

**Documented** means the dedicated space on the current medication chart (defined below) has been completed in a way that is consistent with instructions in the NPS MedicineWise National Inpatient Medication Chart online training course, as follows:

- if there are no known ADRs this should be documented on the medication chart as “nil known”
- if no information is known about the patient’s ADR status, for example if the patient is unable to communicate, this should be documented as “unknown”
- where previous reactions are known, the reaction, type and date should be explicitly documented. If the reaction type or date is unknown, this should be explicitly documented. If there is not enough space to explain the reaction type or date in full, a note should be made to refer to the patient’s medical record for more detail.

**The current medication chart** refers to the NIMC or other chart approved for use by the hospital drug and therapeutics committee.
Data collection for local use

Please refer to the section Using the National Quality Use of Medicines Indicators for Australian Hospitals for guidance on sample selection, sample size, measurement frequency and other considerations.

**Inclusion criteria:** Current adult, paediatric and neonatal inpatients.

**Exclusion criteria:** Nil.

**Recommended data sources:** Medication charts.

The data collection tool for QUM Indicator 3.2 assists data collection and indicator calculation.

## Data collection for inter-hospital comparison

This indicator may be suitable for inter-hospital comparison. In this case, definitions, sampling methods and guidelines for audit and reporting need to be agreed in advance in consultation with the coordinating agency.

### Indicator calculation

\[
\text{Numerator} \times 100\% \quad \text{Denominator}
\]

**Numerator** = Number of patients whose known ADRs are documented on the current medication chart

**Denominator** = Number of patients in sample

### Limitations and interpretation

Data collection for this indicator relies on documentation of ADRs on the medication chart and in the medical record. Good documentation supports quality patient care\(^6\) and is a critical component of management. Poor communication can result in adverse medicine events.\(^7\)

Recording a detailed medication history at admission is a critical step in determining the accuracy and completeness of the list of known ADRs. This indicator does not assess the accuracy of the list of known ADRs documented in the medical record, but rather focuses on availability of complete documentation at the point of prescribing, dispensing and administration, i.e. on the medication chart.
Further information


Guidelines for detailed medication history taking and ADR management have been published by the Society of Hospital Pharmacists of Australia. Medication Safety Self Assessment for Australian Hospitals (MSSA) can help identify potential strategies for improvement with this and other indicators. The MSSA encourages development of robust systems for safe prescribing, dispensing, administration and monitoring of medicines. The MSSA is available at www.cec.health.nsw.gov.au

This indicator can be used to assist hospitals in meeting the National Safety and Quality Health Service Standard 1 [items 1.2.1, 1.2.2, 1.5.2, 1.6.1, 1.6.2, 1.8.1] and Standard 4 [items 4.1.1, 4.2.1, 4.2.2, 4.4.2, 4.5.1, 4.5.2, 4.6.1, 4.7.1, 4.7.2] and Standard 6 [items 6.1.1, 6.2.1, 6.3.1].

References